Stay updated on Combining GEN0101 and Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Combining GEN0101 and Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Combining GEN0101 and Pembrolizumab in Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new Locations section is added, listing Osaka and additional prefectures (Aichi-ken, Hokkaido, Kumamoto, Shizuoka, Tokyo) and the page revision updated to v3.3.3. The HHS Vulnerability Disclosure link and prior location entries (Aichi-ken Locations, Hokkaido Locations, Kumamoto Locations, Shizuoka Locations, Tokyo Locations) were removed.SummaryDifference0.6%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedRevision tag updated from v3.3.1 to v3.3.2 on the Study Details page. No study data, eligibility criteria, outcomes, or locations appear to be affected.SummaryDifference0.1%

- Check42 days agoChange DetectedMinor site revision update from v3.2.0 to v3.3.1; no changes to study content or essential page details were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedThe government funding and operating status notice has been removed from the page.SummaryDifference0.4%

- Check63 days agoChange DetectedNo significant changes were observed in the page content; only minor non-substantive UI tweaks were seen. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check92 days agoChange DetectedAdded a government-funding notice and updated to version v3.2.0; removed reference to v3.1.0.SummaryDifference3%

Stay in the know with updates to Combining GEN0101 and Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combining GEN0101 and Pembrolizumab in Melanoma Clinical Trial page.